Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical News Today (MNT)
In neuro-oncology, where many of the therapies are expensive, toxic, and difficult to access, the idea that a low-cost, generic medication might help slow a tumor like glioblastoma is extremely attractive.
Neurology December 1st 2025
Neuro-Oncology
Long-term follow-up data demonstrate a significant overall survival advantage with combination therapy, showing a hazard ratio of 0.54 (95% CI 0.31-0.95) for radiation plus temozolomide versus radiation alone in grade II gliomas.
Neurology February 20th 2025